- Home
- YY vs BEAM Comparison
YY vs BEAM Comparison
Compare YY & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YY
- BEAM
- Stock Information
- Founded
- YY 2005
- BEAM 2017
- Country
- YY Singapore
- BEAM United States
- Employees
- YY N/A
- BEAM N/A
- Industry
- YY EDP Services
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- YY Technology
- BEAM Health Care
- Exchange
- YY Nasdaq
- BEAM Nasdaq
- Market Cap
- YY 1.9B
- BEAM 1.9B
- IPO Year
- YY 2012
- BEAM 2020
- Fundamental
- Price
- YY $42.36
- BEAM $26.75
- Analyst Decision
- YY Hold
- BEAM Buy
- Analyst Count
- YY 3
- BEAM 10
- Target Price
- YY $35.00
- BEAM $47.67
- AVG Volume (30 Days)
- YY 706.9K
- BEAM 1.1M
- Earning Date
- YY 11-26-2024
- BEAM 02-25-2025
- Dividend Yield
- YY 1.93%
- BEAM N/A
- EPS Growth
- YY N/A
- BEAM N/A
- EPS
- YY 3.11
- BEAM N/A
- Revenue
- YY $2,258,181,000.00
- BEAM $349,643,000.00
- Revenue This Year
- YY $0.62
- BEAM N/A
- Revenue Next Year
- YY $1.84
- BEAM $10.82
- P/E Ratio
- YY $13.17
- BEAM N/A
- Revenue Growth
- YY N/A
- BEAM 328.73
- 52 Week Low
- YY $27.88
- BEAM $20.84
- 52 Week High
- YY $42.76
- BEAM $49.50
- Technical
- Relative Strength Index (RSI)
- YY 63.90
- BEAM 53.85
- Support Level
- YY $40.30
- BEAM $27.75
- Resistance Level
- YY $41.63
- BEAM $29.52
- Average True Range (ATR)
- YY 1.65
- BEAM 1.87
- MACD
- YY 0.09
- BEAM -0.03
- Stochastic Oscillator
- YY 95.41
- BEAM 55.30
About YY JOYY Inc.
JOYY Inc is a global technology company offering comprehensive innovation capabilities. The company enables users to interact with others in real time. The group is actively exploring and expanding its global commerce Software-as-a-Service and solutions business. JOYY emphasizes technological innovation and is recognized in the industry for its significant number of patent applications and licenses.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.